



the 2016 meeting, 14 PRP have attended 2 or more GRAPPA-related events, and 6 have been to 5 or more events.

GRAPPA activities in which PRP have been and are currently involved were highlighted during the meeting. This included the update of the OMERACT PsA core domain set in which PRP were included in all phases of the process. Endorsement of the updated set was obtained with a 90% vote at the OMERACT 2016 meeting. One important feature of the updated core domain set was the movement or inclusion of items to the inner and middle circles (fatigue, participation, emotional well-being) that were of particular importance to patients<sup>3,4</sup>. Additional items important to patients were also added to the research agenda (independence, sleep, treatment burden). PRP are involved in the planned update to the core outcome measurement set scheduled to be presented at OMERACT 2018.

Other activities in which PRP have been involved include the production of *A Patient's Guide to Treatments for Psoriatic Arthritis*, a lay interpretation of the GRAPPA treatment recommendations published earlier this year<sup>5</sup>, the definition of musculoskeletal inflammation, the definition of flare<sup>6</sup>, and the Benchmarking Care in Psoriasis and Psoriatic Arthritis report during the review phase. Activities in which PRP had not been involved at the outset but would be in the future include those related to treat-to-target and composite outcome measures, with a consensus meeting planned to incorporate both PRP and physician viewpoints, as well as research.

Challenges related to PRP engagement that have been highlighted previously<sup>7</sup> were reviewed, including those related to representativeness and the timing to implement PRP participation. Although it was noted that great strides have been made in PRP representativeness related to geographic location, it was acknowledged that none of the PRP had psoriasis only, and whereas 2 Asians and 1 Latino were now a part of the PRP group, the remaining members were all white<sup>8</sup>.

The successful update of the PsA core domain set has emphasized the benefits of PRP engagement in all stages of a project, from beginning to end. This experience suggests that other projects could similarly benefit from comprehensive PRP involvement throughout.

These issues were further analyzed in a PRP breakout session, which was led by a PRP and attended by 1 rheumatologist/researcher, 1 medical student, and 1 industry member. The discussion focused on evaluating the current status of PRP membership in GRAPPA, and identifying opportunities for optimization. The outcomes of the discussions are reported below. Because of the limited number of attendees at the breakout session, especially other PRP, the ideas presented serve as a starting point and undoubtedly will need further exploration and development.

While it was agreed that the currently identified PRP

served as a good-sized core group, additional PRP should be engaged periodically to allow for a continuous refreshing of perspectives. To facilitate education and participation of PRP, current means of communications by e-mail, teleconferences, and Skype would continue to be used. The frequency of these interactions could be expanded as needed to involve PRP identified at a regional or local level to facilitate researcher access for their initiatives.

Currently, some countries and regions are increasing incorporation of the patient voice into their processes guiding the conduct of research or the provision of healthcare; the United Kingdom is 1 such example with the National Health Service, the National Institute for Health and Care Excellence, and the James Lind Alliance<sup>9,10</sup>, all exemplifying opportunities for patient involvement. The United States is another example, where the US Food and Drug Administration has developed multiple routes for patient engagement in the regulatory process to approve new therapeutics and devices, e.g., through the Patient Engagement Advisory Committee, the Patient-Focused Drug Development Program, the Patient Representative Program, and the Drug Development Patient Consultant Program<sup>11,12</sup>. These efforts provide guidance regarding the incorporation of patients to ensure the relevance to patients of the organization's work.

A concern was raised as to whether PRP should be involved in all activities related to GRAPPA. The researcher mentioned a continuing medical education program at which patients presented their experience in a combined clinic for PsA; overall, the feedback from attendees of the program had been positive regarding this educational approach. In another example, it was mentioned that some could consider it sufficient to conduct a patient survey through a patient community to obtain the information required to inform one's research. A counterargument to this approach would be that a PRP could help with the design and wording of the questionnaire to potentially improve the quality and usefulness of the information obtained.

One attendee relayed the experience of a patient representative being excluded from the safety committee of a local hospital board to avoid the perceived constraints imposed on other members by the patient's presence. The potential value of including a patient on the board may have been for other board members to learn what aspects of hospital safety are most important to better address patient needs. In turn, this could improve patient satisfaction with the delivery of care. While it was agreed that engaging patients poses a learning curve for many organizations, no clear scenario was presented in which patient involvement in the process would not positively augment the result.

The industry member indicated that his/her company, like others, is increasingly involving patients in every step of the drug development processes<sup>13</sup>. In doing so, the company carefully defines its interactions with patients to maintain professional boundaries, with research as the main focus.

Regarding potentially involving the PRP at GRAPPA, the industry member reported that he/she would appreciate it if defined variables could be arranged to have PRP, with their agreement, help with the review of informed consent and patient materials, as well as evaluating study designs regarding procedures and time commitments.

Last, it was discussed that as the PRP group within GRAPPA gains experience, they themselves may start to pose and lead the investigation of their own questions related to the disease process. The research agenda items, e.g., independence, from the update of the PsA core domain set would fall into this category. It was suggested that exploration of funding through the Patient-Centered Outcomes Research Institute might be of interest.

PRP have become a part of the fabric of the GRAPPA community. As their role matures within the organization, their voices will be increasingly incorporated into GRAPPA initiatives. Further, with appropriate support, we envision a time when PRP will identify and lead their own projects, thus adding to the growing movement of patient-centric research.

## ACKNOWLEDGMENT

The authors thank Rodrigo Firmino and Glenn Windisch, patient research partners, for their participation in the 2016 GRAPPA meeting.

## REFERENCES

1. Matthias A. The secret to true patient centricity from big pharma's first chief patient officer. [Internet. Accessed February 7, 2017.] Available from: [www.pm360online.com/the-secret-to-true-patient-centricity-from-big-pharmas-first-chief-patient-officer](http://www.pm360online.com/the-secret-to-true-patient-centricity-from-big-pharmas-first-chief-patient-officer)
2. Coates LC, Moverley AR, McParland L, Brown S, Navarro-Coy N, O'Dwyer JL, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial. *Lancet* 2015;386:2489-98.
3. Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. *Ann Rheum Dis* 2016 Sep 9 (E-pub ahead of print).
4. Orbai AM, Mease PJ, de Wit M, Kalyoncu U, Campbell W, Tillett W, et al. Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. *J Rheumatol* 2016;43:965-9.
5. Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. *Arthritis Rheumatol* 2016;68:1060-71.
6. Moverley AR, Waxman R, de Wit M, Parkinson A, Campbell W, Brooke M, et al. Development of a flare instrument for use in psoriatic disease: a report from the 2015 GRAPPA Annual Meeting. *J Rheumatol* 2016;43:974-8.
7. de Wit M, Campbell W, Coates LC, Gladman DD, James J, Lindsay CA, et al. Let's talk about inclusion: a report on patient research partner involvement in the GRAPPA 2015 Annual Meeting. *J Rheumatol* 2016;43:970-3.
8. US Food and Drug Administration, Rockville, MD. Guidance for industry: collection of race and ethnicity data in clinical trials [Internet. Accessed February 7, 2017.] Available from: [www.fda.gov/OHRMS/DOCKETS/98fr/5054dft.doc](http://www.fda.gov/OHRMS/DOCKETS/98fr/5054dft.doc)
9. Partridge N, Scadding J. The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials. *Lancet* 2004;364:1923-4.
10. National Institute for Health Research. Briefing note three: Why involve members of the public in research? [Internet. Accessed February 8, 2017.] Available from: [www.invo.org.uk/posttypresource/why-should-members-of-the-public-be-involved-in-research/](http://www.invo.org.uk/posttypresource/why-should-members-of-the-public-be-involved-in-research/)
11. Hunter NL, Califf RM. Why partnerships are key to the science of patient input. [Internet. Accessed February 7, 2017.] Available from: [blogs.fda.gov/fdavoices/index.php/tag/the-patient-focused-drug-development-pfdd-program](http://blogs.fda.gov/fdavoices/index.php/tag/the-patient-focused-drug-development-pfdd-program)
12. Patel N. A patient-centered approach. [Internet. Accessed February 8, 2017.] Available from: [www.fda.gov/downloads/ForHealthProfessionals/LearningActivities/UCM302525.pdf](http://www.fda.gov/downloads/ForHealthProfessionals/LearningActivities/UCM302525.pdf)
13. Sharma NS. Patient centric approach for clinical trials: current trend and new opportunities. *Perspect Clin Res* 2015;6:134-8.